Today, just over two weeks from the launch of the Open Pharma position statement on open access, we reflect on how the statement came about, the benefits it offers to different types of stakeholders and the success it has had so far.
Featuring news from Peer Review Week, help for smaller scientific societies with the transition to Plan S and recommendations by NIH to make data more FAIR
Featuring the latest results from the Good Pharma Scorecard, the newest signatories to DORA, incentives for sharing data and potential barriers to mandating open access.
Featuring the development of a new evidence framework for discussing hot open science topics that can be used to address misinformation in scientific publishing, the introduction of transparent manuscript-handling processes, and making the costs of clinical trials publicly available.
Featuring the benefits of open data, why the public should be involved in scientific research and countries that are leading the way in open access publishing.
In January 2019, Open Pharma core members and supporters attended a roundtable meeting, hosted by The BMJ at its Head Office at BMA House in London.